These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 38050871)

  • 1. The genomic and immune landscapes of gastric cancer and their correlations with HER2 amplification and PD-L1 expression.
    Jing X; Luo Z; Wu J; Ye F; Li J; Song Z; Zhang Y; Shi M; Sun H; Fang Y; Jiang Y; Ji X
    Cancer Med; 2023 Dec; 12(24):21905-21919. PubMed ID: 38050871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic alteration profile and PD-L1 expression among different breast cancer subtypes in Chinese population and their correlations.
    Li K; Cao L; Li C; Wu J; Chen B; Zhang G; Li X; Wen L; Jia M; Wei G; Lin J; Li Y; Zhang Y; Mok H; Ren C; Wang Y; Qi X; Guo L; Che Y; Liao N
    Cancer Med; 2023 Mar; 12(5):5195-5208. PubMed ID: 36404592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic landscape and its correlations with tumor mutational burden, PD-L1 expression, and immune cells infiltration in Chinese lung squamous cell carcinoma.
    Jiang T; Shi J; Dong Z; Hou L; Zhao C; Li X; Mao B; Zhu W; Guo X; Zhang H; He J; Chen X; Su C; Ren S; Wu C; Zhou C
    J Hematol Oncol; 2019 Jul; 12(1):75. PubMed ID: 31299995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinct genomic landscapes of gastroesophageal adenocarcinoma depending on PD-L1 expression identify mutations in RAS-MAPK pathway and TP53 as potential predictors of immunotherapy efficacy.
    Wang JY; Xiu J; Baca Y; Arai H; Battaglin F; Kawanishi N; Soni S; Zhang W; Millstein J; Shields AF; Grothey A; Weinberg BA; Marshall JL; Lou E; Khushman M; Sohal DPS; Hall MJ; Oberley M; Spetzler D; Shen L; Korn WM; Lenz HJ
    Ann Oncol; 2021 Jul; 32(7):906-916. PubMed ID: 33798656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression Profile of Markers for Targeted Therapy in Gastric Cancer Patients: HER-2, Microsatellite Instability and PD-L1.
    Pereira MA; Ramos MFKP; Dias AR; Faraj SF; Ribeiro RRE; de Castria TB; Zilberstein B; Alves VAF; Ribeiro U; de Mello ES
    Mol Diagn Ther; 2019 Dec; 23(6):761-771. PubMed ID: 31595457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathological features of tumor mutation burden, Epstein-Barr virus infection, microsatellite instability and PD-L1 status in Chinese patients with gastric cancer.
    Zhang L; Wang Y; Li Z; Lin D; Liu Y; Zhou L; Wang D; Wu A; Li Z
    Diagn Pathol; 2021 May; 16(1):38. PubMed ID: 33933102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
    Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
    Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Landscape and Clinical Implication of CCNE1-amplified Esophagogastric Cancer.
    Rustgi N; Wu S; Samec T; Walker P; Xiu J; Lou E; Goel S; Saeed A; Moy RH
    Cancer Res Commun; 2024 Jun; 4(6):1399-1409. PubMed ID: 38717153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bridging genomics and phenomics of gastric carcinoma.
    Cho J; Ahn S; Son DS; Kim NK; Lee KW; Kim S; Lee J; Park SH; Park JO; Kang WK; An JY; Choi MG; Lee JH; Sohn TS; Bae JM; Kim S; Kim KM
    Int J Cancer; 2019 Nov; 145(9):2407-2417. PubMed ID: 30801717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic profiles and their associations with TMB, PD-L1 expression, and immune cell infiltration landscapes in synchronous multiple primary lung cancers.
    Hu C; Zhao L; Liu W; Fan S; Liu J; Liu Y; Liu X; Shu L; Liu X; Liu P; Deng C; Qiu Z; Chen C; Jiang Y; Liang Q; Yang L; Shao Y; He Q; Yu D; Zeng Y; Li Y; Pan Y; Zhang S; Shi S; Peng Y; Wu F
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive analysis of potential immunotherapy genomic biomarkers in 1000 Chinese patients with cancer.
    Zang YS; Dai C; Xu X; Cai X; Wang G; Wei J; Wu A; Sun W; Jiao S; Xu Q
    Cancer Med; 2019 Aug; 8(10):4699-4708. PubMed ID: 31270941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors.
    Goodman AM; Piccioni D; Kato S; Boichard A; Wang HY; Frampton G; Lippman SM; Connelly C; Fabrizio D; Miller V; Sicklick JK; Kurzrock R
    JAMA Oncol; 2018 Sep; 4(9):1237-1244. PubMed ID: 29902298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarkers in Breast Cancer: An Integrated Analysis of Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry Biomarkers in 312 Patients with Breast Cancer.
    Huang RSP; Li X; Haberberger J; Sokol E; Severson E; Duncan DL; Hemmerich A; Edgerly C; Williams E; Elvin J; Vergilio JA; Killian JK; Lin D; Hiemenz M; Xiao J; McEwan D; Holmes O; Danziger N; Erlich R; Frampton G; Cohen MB; McGregor K; Reddy P; Cardeiro D; Anhorn R; Venstrom J; Alexander B; Brown C; Pusztai L; Ross JS; Ramkissoon SH
    Oncologist; 2020 Nov; 25(11):943-953. PubMed ID: 32869930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-L1 and HER2 expression in gastric adenocarcinoma and their prognostic significance.
    Lian J; Zhang G; Zhang Y; Liu H; Zhang J; Nan P; Tian W
    Dig Liver Dis; 2022 Oct; 54(10):1419-1427. PubMed ID: 35123909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinic-Pathological Characteristics and Prognostic Value of PD-L1 and HER2 in Gastric Cancer.
    Chen L; Wang L; Li X; Zhang G; Li Z; Wang Y
    DNA Cell Biol; 2021 Feb; 40(2):405-413. PubMed ID: 33605797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristics of the immunogenicity and tumor immune microenvironment in
    Wang Q; Mao Z; Li W; Wang S; Wang L; Chen L; Yang Z; Fu X; Jiang P; Bai Y; Xu L; Zhang S; Hou Y; Jia X; Jiang L; Liu M; Zhang G; Jiang Y; Guo H
    Front Immunol; 2022; 13():1042072. PubMed ID: 36591290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-L1 expression is associated with massive lymphocyte infiltration and histology in gastric cancer.
    Li Z; Lai Y; Sun L; Zhang X; Liu R; Feng G; Zhou L; Jia L; Huang X; Kang Q; Lin D; Gao J; Shen L
    Hum Pathol; 2016 Sep; 55():182-9. PubMed ID: 27260946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Profiles of PD-1, PD-L1, PD-L2 in Gastric Cancer and Their Relation with Mutation, Immune Infiltration, and Survival.
    Liu J; Li H; Sun L; Yuan Y; Xing C
    Biomed Res Int; 2020; 2020():2496582. PubMed ID: 32596285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional loss of ARID1A is tightly associated with high PD-L1 expression in gastric cancer.
    Kim YB; Ahn JM; Bae WJ; Sung CO; Lee D
    Int J Cancer; 2019 Aug; 145(4):916-926. PubMed ID: 30664822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune microenvironment features and efficacy of PD-1/PD-L1 blockade in non-small cell lung cancer patients with EGFR or HER2 exon 20 insertions.
    Chen K; Pan G; Cheng G; Zhang F; Xu Y; Huang Z; Fan Y
    Thorac Cancer; 2021 Jan; 12(2):218-226. PubMed ID: 33210451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.